New Enterprise Associates 16, L.P.
SEC-identified person · CIK 1694560 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Trevi Therapeutics, Inc. TRVI | Officer | filed 2019 - 2026 |
| Neuehealth, Inc. NEUE | Director | filed 2024 - 2025 |
| Tapimmune INC. TPIV.OB | Officer | filed 2018 - 2024 |
| Mirum Pharmaceuticals, Inc. MIRM | Officer | filed 2019 - 2023 |
| Akouos, Inc. AKUS | Officer | filed 2020 - 2022 |
| Genocea Biosciences, INC. GNCA | Officer | filed 2018 - 2022 |
| Metacrine, Inc. MTCR | Officer | filed 2020 - 2021 |
| Regulus Therapeutics Inc. RGLS | Officer | filed 2017 - 2021 |
| Black Diamond Therapeutics, Inc. BDTX | Officer | filed 2020 - 2020 |
| X4 Pharmaceuticals, Inc XFOR | Officer | filed 2017 - 2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.